Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Cyclacel Pharmaceuticals, Inc. (CYCC) Posts Q4 Loss of 19c/Share
March 25, 2014 4:05 PM EDTCyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q4 EPS of ($0.19), $0.14 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $299 thousand versus the consensus estimate of $90 thousand.
For earnings history and earnings-related data on Cyclacel Pharmaceuticals, Inc. (CYCC) click here.... More
